ASHEVILLE, N.C., Aug. 21, 2013 /PRNewswire-iReach/ -- Data from multiple in-service clinical trials and research studies involving hundreds of patients using Theraworx™ at more than a dozen hospitals are showing positive results and signaling progress battling one of the most prevalent healthcare-associated infections (HAI), catheter-associated urinary tract infections, or CAUTI.
Theraworx is an all-natural, skin-friendly topical solution that is applied for pre-insertion and post-catheter perineal cleaning, and incontinence skin care treatment. It has become a key factor at medical facilities adopting a patient-focus safety strategy to address CAUTIs, the greatest single source of HAIs, costing U.S. hospitals $3 billion annually.
Some 900,000 patients a year develop a CAUTI while in U.S. hospitals, and 13,000+ patients die annually when bacteria from that infection enters the kidneys, making this an important patient safety issue. A typical 165-bed hospital can incur more than $525,000 annually in costs to fight urinary tract infections. Medicare does not pay hospitals for CAUTI readmissions, which can cost upwards of $10,000 or more per patient.
Over the past three years there has been extensive data analysis from trials of Theraworx in clinical settings. Most notably, a large academic medical center in the Midwest conducted sequential 90-day trials covering more than 400 patients in its ICU and operating rooms. Theraworx was used prior to Foley catheter insertion for peri-care and cleaning, achieving greater than 70 percent CAUTI reduction in each test period.
"Hospitals are realizing that if they initiate a proactive program to curb CAUTI and other infections with our proven protocol that they will see improvement quickly," said Steve Woody, president of Avadim LLC. "This is particularly significant now due to Medicare readmission penalties, pay-for-performance metrics and HAI reporting requirements that bring quite punitive consequences."
IRB studies further validate Theraworx effectiveness
Two hospital-sponsored, clinical-use research studies, both evaluated and approved by the Institutional Review Board (IRB), will be published this year that document, in detail, the use of Theraworx with a new clinical protocol that drastically curbs CAUTI. One IRB-approved study concluded recently at 300-bed medical/ surgical hospital in Kentucky, with results expected to be published in early fall.
Produced by Avadim LLC, Theraworx is non-CHG total body pH and hygiene management solution that supports the function of the skin's natural immune system. For peri-care, a single-use 2-pack of disposable cloths is easily added to catheter bundles providing a cost-cutting, yet highly effective solution. In addition, a companion non-aerosol foam or spray bottle of Theraworx is available to continue maintenance and post-discharge incontinence care. For more information call 877-677-2723, visit http://www.theraworx.com or write to StopCAUTI@theraworx.com.
Media Contact: Jared Buckner, Avadim LLC, 877-677-2723, jared@Theraworx.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Avadim LLC